09939 KINTOR PHARMA-B
- 1.210
- +0.150+14.15%
KINTOR PHARMA-B News
Pioneering the Pharmaceutical Industry (09939.HK): Pucluramide and Frethane have made many advances, allotted shares and increased cash availability
Pioneering Pharmaceutical-B (09939.HK): Pucluramide, which focuses on AR targets, is expected to be approved to treat COVID-19
Kaituo Pharmaceutical-B (09939.HK) 2021 Interim Report Review: Core Product Clinical Trials Advance Smoothly: Clinical Trials of Core Products Proceed Successfully, the Specific Oral COVID-19 Drug Pucluramide Wins First EUA
Pioneering Pharmaceutical-B (9939.HK): Strong pipeline advancement
Pioneering Pharmaceutical-B (09939.HK): Actively preparing for commercialization and focusing on disclosure of key clinical data
Pioneering Pharmaceutical-B (09939.HK): The pipeline layout is getting fuller, and commercialization of core products begins
Pioneering Pharmaceutical-B (9939.HK): Global expansion of procluramide sets sail
Pioneering Pharmaceutical-B (9939.HK): Pioneering COVID-19 Treatment Ushers in New Opportunities
Pioneering Pharmaceutical-B (9939.HK) Pioneering Portraits: Starting with COVID-19 Oral Specific Drugs, Opening Up the Sea of Stars for AR Applications
Overseas Healthcare Sector Weekly Report: BeiGene updates zebutinib research data, biotechnology sector leads the industry
Pioneering Pharmaceutical-B (09939.HK) In-depth Research Report: Leading AR Industry Has Great Potential for COVID-COVID/Hair Loss/Acne Indications
First coverage of Pioneer Pharmaceutical (9939.HK): Accelerating R&D pipeline commercialization based on AR platforms is imminent
Pioneer Pharmaceutical-B (9939.HK) 1H20 performance: pucluramide is expected to submit NDA in China in 4Q20
Pioneer Pharmaceutical (9939.HK): An innovator in drug development for AR-related diseases; first coverage gave a “buy” rating
Kaituo Pharmaceutical Co., Ltd. (9939.HK)
Pioneer Pharmaceutical (09939.HK)
Kaituo Pharmaceutical Co., Ltd. - B (9939.HK): IPO News
Analysis
Price Target
No Data
